Abstract:Opioids are the cornerstone therapy for the treatment of moderate to severe pain. Although common concerns regarding the use of opioids include the potential for detrimental side effects, physical dependence, and addiction, accumulating evidence suggests that opioids may yet cause another problem, often referred to as opioid-induced hyperalgesia. Somewhat paradoxically, opioid therapy aiming at alleviating pain may render patients more sensitive to pain and potentially may aggravate their preexisting pain. Thi… Show more
“…Most evidence for OIH derives from animal studies or studies in healthy volunteers, while investigations in clinical settings revealed varying results [21,22]. As short-acting opioids are particularly suspected to be associated with OIH, there are a number of studies demonstrating states of hyperalgesia following remifentanil exposure [23].…”
Background: Short-acting opioids like remifentanil are suspected of an increased risk for tolerance, withdrawal and opioid-induced hyperalgesia (OIH). These potential adverse effects have never been investigated in neonates. Objectives: To compare remifentanil and fentanyl concerning the incidence of tolerance, withdrawal and OIH. Methods: 23 mechanically ventilated infants received up to 96 h either a remifentanil- or fentanyl-based analgesia and sedation regimen with low-dose midazolam. We compared the required opioid doses and the number of opioid dose adjustments. Following extubation, withdrawal symptoms were assessed by a modification of the Finnegan score. OIH was evaluated by the CHIPPS scale and by testing the threshold of the flexion withdrawal reflex with calibrated von Frey filaments. Results: Remifentanil had to be increased by 24% and fentanyl by 47% to keep the infants adequately sedated during mechanical ventilation. Following extubation, infants revealed no pronounced opioid withdrawal and low average Finnegan scores in both groups. Only 1 infant of the fentanyl group and 1 infant of the remifentanil group required methadone for treatment of withdrawal symptoms. Infants also revealed no signs of OIH and low CHIPPS scores in both groups. The median threshold of the flexion withdrawal reflex was 4.5 g (IQR = 2.3) in the fentanyl group and 2.7 g (IQR = 3.3) in the remifentanil group (p = 0.312), which is within the physiologic range of healthy infants. Conclusions: Remifentanil does not seem to be associated with an increased risk for tolerance, withdrawal or OIH.
“…Most evidence for OIH derives from animal studies or studies in healthy volunteers, while investigations in clinical settings revealed varying results [21,22]. As short-acting opioids are particularly suspected to be associated with OIH, there are a number of studies demonstrating states of hyperalgesia following remifentanil exposure [23].…”
Background: Short-acting opioids like remifentanil are suspected of an increased risk for tolerance, withdrawal and opioid-induced hyperalgesia (OIH). These potential adverse effects have never been investigated in neonates. Objectives: To compare remifentanil and fentanyl concerning the incidence of tolerance, withdrawal and OIH. Methods: 23 mechanically ventilated infants received up to 96 h either a remifentanil- or fentanyl-based analgesia and sedation regimen with low-dose midazolam. We compared the required opioid doses and the number of opioid dose adjustments. Following extubation, withdrawal symptoms were assessed by a modification of the Finnegan score. OIH was evaluated by the CHIPPS scale and by testing the threshold of the flexion withdrawal reflex with calibrated von Frey filaments. Results: Remifentanil had to be increased by 24% and fentanyl by 47% to keep the infants adequately sedated during mechanical ventilation. Following extubation, infants revealed no pronounced opioid withdrawal and low average Finnegan scores in both groups. Only 1 infant of the fentanyl group and 1 infant of the remifentanil group required methadone for treatment of withdrawal symptoms. Infants also revealed no signs of OIH and low CHIPPS scores in both groups. The median threshold of the flexion withdrawal reflex was 4.5 g (IQR = 2.3) in the fentanyl group and 2.7 g (IQR = 3.3) in the remifentanil group (p = 0.312), which is within the physiologic range of healthy infants. Conclusions: Remifentanil does not seem to be associated with an increased risk for tolerance, withdrawal or OIH.
“…-неможливість або обмеження використання ефективних сучасних методів післяопераційної анал-гезії та переконання частини лікарів, що такі діти є менш чутливими до болю [4].…”
Section: обґрунтування дослідженняunclassified
“…Карагеніновий набряк відтво-рювали сублантарним введенням 0,05 мл 1 % р озчи-ну карагеніну (Sigma, USA) в праву задню кінцівку тварини [4]. Спостереження за розвитком простаг-ландинового набряку у тварин обох статей прово-дили на 3-й годині (піку розвитку) після введення флогогену.…”
СИНДРОМ ГІПЕРАЛЬГЕЗІЇ У ТВАРИН ТА МЕТОДИ ЙОГО ЛІКУВАННЯ ЗА : гіперальгезія, анальгезія, кортизол, гіперглікемія, карагенін, провідникова анестезія, бупі-вакаїн, фентаніл, кетамін
“…It has also been observed with long-term use of hydrocodone, oxycodone as well as methadone. [2][3][4] We diagnosed OIH in our patient, who was implanted a morphine intrathecal pump to control her pain due to adenocarcinoma rectum, chemotherapy, and radiotherapy. She developed hyperalgesia after a span of 1 year as seen on dose escalation on refilling the pump during regular follow-ups.…”
Reported are cases of opioid-induced hyperalgesia (OIH) which is a rare entity to be seen by pain physicians. It occurs in patients treated with long term opioids which is perceived in the form of hyperalgesia or allodynia. It is a clinical challenge to treat such cancer patients and opioid addict individuals. The understand ing of OIH mechanism, manifesta tions as well as treatment is important for any pain physician.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.